Acasti Announces Fourth Quarter and Fiscal Year Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Acasti Announces Fourth Quarter and Fiscal Year Results

LAVAL, QUÉBEC--(Marketwired - May 25, 2016) - Acasti Pharma Inc. (" Acasti " or the " Corporation ") (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars.

"As announced recently, we are delighted with the arrival of our new CEO next week, Ms. Jan D'Alvise's. With her experience and caliber, we believe she will provide strong leadership to Acasti as we exploit the full potential of CaPre, our first product for hypertriglyceridemia," said Dr. Roderick Carter, Acasti's Chairman.

On December 16, 2015, Acasti announced that it had made important progress in its correspondence with the US Food and Drug Administration (FDA) regarding next steps in the development plans for CaPre®. "As planned, we initiated and recently completed subject enrollment for the bioavailability bridging study," highlighted Pierre Lemieux, PhD, Acasti's Chief Operating Officer. "We are expecting results of the study before the end of the year which should confirm our chosen regulatory pathway."

Fourth Quarter Financial Results

  • Revenues were $21,000 for the quarter ended February 29, 2016, versus $178,000 for the quarter ended February 28, 2015
  • Research and development (R&D) expenses were $1,829,000 for the quarter, down from $2,343,000 in the quarter last year
  • Non-IFRS operating loss (1) was $1,163,000 for the quarter, versus $2,263,000 in the quarter last year
  • Net loss was $1,919,000 or $0.18 loss per share for the quarter, versus a net loss of $2,311,000 or $0.21 loss per share in the quarter last year

R&D expenses were lower for the current quarter in comparison with last year largely due to delays in some contract expenses related to Acasti's clinical trials partly offset by an impairment of intangible asset.

The year-over-year decline in Non-IFRS operating loss was largely due to lower R&D expenses.

Fiscal Year Financial Results

  • Revenues were $38,000 for the fiscal year ended February 29, 2016, versus $271,000 for the year ended February 28, 2015
  • Research and development expenses were $7,389,000 for the year, down from $8,857,000 in the prior year
  • Non-IFRS operating loss was $6,569,000 for the year, versus $8,506,000 in the prior year
  • A net loss of $6,317,000 or $0.59 loss per share was recorded for the year, versus a net loss of $1,655,000 or $0.16 loss per share in the prior year.

(1) See comment on Non-IFRS operating loss which follows

The year-over-year variances for the fiscal year are mainly attributable to the same factors highlighted above for the three-months ended February 29, 2016.

Cashflows

Cash and short-term investment were $12.5 million as at February 29, 2016 of which $2 million was considered as restricted short-term investment.

CaPre ® Development Plan

As previously announced, Acasti intends to pursue the regulatory pathway for CaPre® under section 505(b)(2) (2) of the Federal Food, Drug, and Cosmetic Act. In conjunction with this, Acasti has recently submitted an amendment to its original FDA Investigational New Drug (IND) application to commence a pivotal bioavailability bridging study, comparing CaPre® to an omega-3 prescription drug as a means of establishing a scientific bridge between the two. The bridging study will help determine the feasibility of a 505(b)(2) regulatory pathway, while also optimizing the protocol design of a Phase 3 trial.

The 505(b)(2) approval pathway has been used by many other companies and Acasti's regulatory and clinical experts believe such a strategy is best for CaPre®. This should allow the Corporation to further optimize the advancement of CaPre®, while benefiting most importantly from the substantial clinical and nonclinical data already available with another FDA-approved omega-3 prescription drug. In addition, it should reduce the expected expenses and streamline the overall CaPre® development program required to support a New Drug Application (NDA) submission.

(2) See note on "505(b)(2) Regulatory Pathway"

505(b)(2) Regulatory Pathway

The 505(b)(2) regulatory pathway is defined in The Federal Food Drug and Cosmetics Act as a New Drug Application (NDA) containing investigations of safety and effectiveness that are being relied upon for approval and were not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. These applications differ from the typical NDA (described under Section 505(b)(1) of the Act), in that they allow a sponsor to rely, at least in part, on the FDA's findings of safety and/or effectiveness for a previously approved drug.

Caution Regarding Non-IFRS Financial Measures

The Corporation uses adjusted financial measures, including Non-IFRS operating loss (Loss from operating activities before interest, taxes, depreciation and amortization and impairment loss), to assess its operating performance. These non-IFRS financial measures are directly derived from the Company's financial statements and are presented in a consistent manner. The Company uses these measures for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to plan and forecast for future periods as well as to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to IFRS measures, allows them to see the Company's results through the eyes of management, and to better understand its historical and future financial performance. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Corporation uses Non-IFRS operating loss to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends its operating performance, and because the Corporation believes it provides meaningful information on the Corporation's financial condition and operating results. Acasti's method for calculating Non-IFRS operating loss may differ from that used by other corporations.

Acasti obtains its Non-IFRS operating loss measurement by adding to net loss, finance costs, depreciation and amortization, impairment loss and income taxes and by subtracting finance income. Finance income/costs include foreign exchange gain (loss) and change in fair value of derivatives. Acasti also excludes the effects of certain non-monetary transactions recorded, such as stock-based compensation, from its Non-IFRS operating loss calculation. The Corporation believes it is useful to exclude this item as it is a non-cash expense. Excluding this item does not imply it is necessarily nonrecurring.

About Acasti Pharma Inc.

Acasti is an emerging biopharmaceutical company focused on the research and development of a prescription drug candidate, CaPre®, for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream. CaPre® is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present as a combination of phospholipid esters and free fatty acids. Krill is a major source of phospholipids and omega-3 fatty acids well known to be beneficial for human health.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Acasti's latest Annual Information Form, which also forms part of Acasti's latest annual report on Form 20-F, and which is available on SEDAR at www.sedar.com , on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Acasti's website at acastipharma.com (the "AIF"). All forward-looking statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Acasti's public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors".

Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Acasti Contact: Mario Paradis VP and CFO +1.450.687.2262 m.paradis@acastipharma.com www.acastipharma.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 97

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 194

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 106

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 21

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 0

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 86

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 97

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 133

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading

Top 5 Most Recently Viewed Articles

BexBack Launches High-Leverage Trading with Exciting Bonuses

Updated Category News Views 176

Exciting New Trading Features from BexBack BexBack, a leading cryptocurrency exchange platform, is thrilled to reveal its latest trading enhancements, designed for traders eager to amplify their market position. These innovative features are now accessible to users across the globe, marking a significant step in meeting the soaring demand for high-leverage crypto trading....

Continue Reading
BigBear.ai Partners for AI Innovation Amid Stock Surge

Updated Category News Views 208

BigBear.ai Stock Rises Dramatically BigBear.ai, Inc. (NASDAQ:BBAI) shares have experienced a substantial increase recently. This surge comes after the company announced a significant partnership aimed at enhancing its AI solutions tailored to national security needs. The latest development involves collaboration with another entity to create advanced AI-enabled hardware....

Continue Reading
Totalkredit A/S Unveils Latest Prepayment Data Insights

Updated Category News Views 289

Understanding Recent Prepayment Updates from Totalkredit A/S To all interested parties, Prepayments (CK93) In adherence to the Danish Capital Markets Act, Totalkredit A/S has made available its latest prepayment data. This release reflects the status as of May 2, 2025, and is presented in an accessible format. This information will be efficiently distributed through...

Continue Reading
Examining Coherent's Earnings Outlook and Market Trends

Updated Category News Views 126

Anticipating Coherent's Earnings Report Coherent (NYSE: COHR) is preparing to announce its quarterly earnings soon. Investors are keenly observing the financial landscape to glean insights prior to the release. Analysts predict an earnings per share (EPS) of $0.84, setting the stage for interesting discussions. Investor Expectations Optimism surrounds the forthcoming...

Continue Reading
Exciting Leadership Change at Focus Financial Partners Inc.

Updated Category News Views 319

Leadership Transition at Focus Financial Partners Focus Financial Partners Inc., a prominent player in wealth management and related financial services, has announced a significant leadership change with the appointment of Jason Dubinsky as the new Chief Financial Officer. This transition marks an important chapter for the company, with Mr. Dubinsky set to join in March....

Continue Reading